Strongbridge Biopharma plc to Present at the 37th Annual Cowen and Company Healthcare Conference and the 29th Annual ROTH Con...

Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, will present at the 37th Annual Cowen and Company Healthcare Conference and the 29th Annual ROTH Conference.  The details of the conferences are as follows:

37th Annual Cowen and Company Healthcare Conference Wednesday, March 8, 2017 at 11:20 am ET The Boston Marriott Copley Place, Boston, MA

29th Annual ROTH ConferenceMonday, March 13 at 12:30 pm PT The Ritz Carlton, Dana Point, CA

The Company’s presentations will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge Biopharma Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.

Contacts

Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
[phone]
[e-mail]

Investor Relations
The Trout Group
Marcy Nanus
[phone]
[e-mail]

USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. [phone]
Fax. [phone]